Article: Unlocking the Potential of CAR-T Therapies for Solid Tumors
The recent FDA approval of the very first CAR-T therapy marks a significant milestone in the field of cell and gene therapy. However, this also hastens the need to streamline cell therapy workflows to make them more cost-effective, scalable, and safe, and to find solutions to replicate clinical success in solid tumors.
Read the interview by Dr. Tamara Laskowsky titled ‘Unlocking the Potential of CAR-T Therapies for Solid Tumors’ in which she describes the progress researchers at MD Anderson Cancer Center are making in developing off-the-shelf immunotherapies for the treatment of solid tumor malignancies and how the Incucyte® Live-Cell Analysis System and Intellicyt iQue® Screener PLUS technologies have been integral in advancing their research.
